EPO Patent Publication: Hydroquinazoline Derivatives for Disease Treatment

The European Patent Office has published patent application EP4673431A1 for Novartis AG, detailing hydroquinazoline derivatives for treating diseases or disorders. The publication includes a list of inventors and IPC classifications related to chemical compounds and their therapeutic applications.

EPO Patent Application: Silicon Nanoparticles for Kidney Disease Treatment

The European Patent Office has published a patent application (EP4495059A2) for Osaka University concerning silicon nanoparticles for use in treating kidney diseases. The application details specific IPC classifications related to pharmaceutical compositions and therapeutic uses.

Translate Bio mRNA Patent EP4529928A2 Publication

The European Patent Office has published patent application EP4529928A2 concerning mRNA compositions, methods, and uses, filed by Translate Bio, Inc. The patent is scheduled for publication on March 18, 2026, and covers various applications including cancer treatment.

EPO Patent Bulletin: Assays for Diagnosing Fabry Disease Treatment Options

The European Patent Office has published patent application EP4541418A2 concerning assays for diagnosing and evaluating treatment options for Fabry disease. The application lists Amicus Therapeutics, Inc. and the National Institutes of Health as applicants.

EPO Patent Application: Metformin and Sitagliptin Tablet Formulation

The European Patent Office published patent application EP4563143A1 concerning a bilayer tablet formulation of Metformin and Sitagliptin that includes an antioxidant. The application was filed by Sanovel Ilac Sanayi ve Ticaret A.S. and lists Fatih Sunel, Nur Pehlivan Akalin, and Guldeniz Tunc as inventors.

EPO Patent: Neural Disorder Treatment via Plasminogen Cascade Modulation

The European Patent Office has published a patent application (EP2024194382A1) detailing methods for preventing or treating neural disorders by modulating the plasminogen-plasmin cascade. The patent application was published on March 18, 2026, and covers designated states within the European Union.

EPO Patent Publication: Phyto-Compositions

The European Patent Office published patent application EP4661839A1 for Phyto-Compositions on March 18, 2026. The applicant is Phytoheal Medtech International. This publication details new compositions and their potential applications.

Pfizer Inc. Patent on Nucleic Acids for Therapeutic Uses

The European Patent Office has published patent application EP4661903A1 by Pfizer Inc. concerning nucleic acids for therapeutic uses. This publication details specific nucleic acid sequences and their applications, potentially impacting future drug development and intellectual property within the EU.

EPO Patent: P38 Map Kinase Inhibitors for Cancer Immunotherapy

The European Patent Office has published patent application EP4648772A1 concerning P38 map kinase inhibitors for use in treating cancer immunotherapy-associated cytokine release syndrome. The patent is assigned to Poolbeg Pharma (UK) Limited.

EPO Patent Filing: HIV-Neutralizing Antibodies by Theraclone Sciences

The European Patent Office (EPO) has published a patent application (EP4549461A2) filed by Theraclone Sciences, Inc., The Scripps Research Institute, and International AIDS Vaccine Initiative for HIV-neutralizing antibodies. The patent publication date is March 18, 2026.